Current Status of Novel Agents for the Treatment of B Cell Malignancies: What’s Coming Next?
Open Access
Abstract
Resistance to death is one of the hallmarks of human B cell malignancies and often contributes to the lack of a lasting response to today’s commonly used treatments. Drug discovery approaches designed to activate the death machinery have generated a large number of inhibitors of anti-apoptotic proteins from the B-cell lymphoma/leukemia 2 family and the B-cell receptor (BCR) signaling pathway. Orally administered small-molecule inhibitors of Bcl-2 protein and BCR partners (e.g., Bruton’s tyrosine kinase and phosphatidylinositol-3 kinase) have already been included (as monotherapies or combination therapies) in the standard of care for selected B cell malignancies. Agonistic monoclonal antibodies and their derivatives (antibody–drug conjugates, antibody–radioisotope conjugates, bispecific T cell engagers, and chimeric antigen receptor-modified T cells) targeting tumor-associated antigens (TAAs, such as CD19, CD20, CD22, and CD38) are indicated for treatment (as monotherapies or combination therapies) of patients with B cell tumors. However, given that some patients are either refractory to current therapies or relapse after treatment, novel therapeutic strategies are needed. Here, we review current strategies for managing B cell malignancies, with a focus on the ongoing clinical development of more effective, selective drugs targeting these molecules, as well as other TAAs and signaling proteins. The observed impact of metabolic reprogramming on B cell pathophysiology highlights the promise of targeting metabolic checkpoints in the treatment of these disorders.Keywords
Funding Information
- Institut National de la Sante et de la Recherche Medicale (INSERM)
- SIRIC-CURAMUS (INCA-DGOS-Inserm_12560)
- Société Française d’Hématologie (SFH)
This publication has 468 references indexed in Scilit:
- The Onco-Embryonic Antigen ROR1 Is Expressed by a Variety of Human CancersThe American Journal of Pathology, 2012
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine, 2012
- Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemiaNature Cell Biology, 2012
- Glucose-Independent Glutamine Metabolism via TCA Cycling for Proliferation and Survival in B CellsCell Metabolism, 2012
- Antibody Fusion Proteins: Anti-CD22 Recombinant Immunotoxin Moxetumomab PasudotoxClinical Cancer Research, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- High Prevalence of Fatty Acid Synthase Expression in Colorectal Cancers in Middle Eastern Patients and Its Potential Role as a Therapeutic TargetAmerican Journal of Gastroenterology, 2009
- Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5aProceedings of the National Academy of Sciences, 2008
- CD22: an inhibitory enigmaImmunology, 2008
- The Hallmarks of CancerCell, 2000